Heart failure & cardiomyopathies
Indirect Comparison of SGLT2 Inhibitors in Patients with Established Heart Failure: Evidence Based on Bayesian Methods
Authors' conclusion
In patients with established heart failure, there was no significant difference of the major efficacy outcomes among SGLT2 inhibitor treatments; however, sotagliflozin may be associated with the lowest risk of the composite of cardiovascular death or hospitalization for heart failure, and dapagliflozin may be associated with the lowest risk of all-cause and cardiovascular mortality.
Study context
- Population
- Patients with established HF5 trials
- Comparison
- Dapagliflozin vs empagliflozin vs sotagliflozin
- Outcome
- Composite of:
- CV death
- Hospitalization for HF
Methodological detailsindirect comparison
- Indirect comparison
Pooled result
As reported in the abstract
CV death or hospitalization for HF
Odds ratio (95% CI)
Dapagliflozinvs Empagliflozin
1.00(0.66–1.55)
Dapagliflozinvs Sotagliflozin
1.54(0.91–2.65)
Empagliflozinvs Sotagliflozin
1.53(0.90–2.69)
Further pooled results
| Outcome | OR (95% CI) | |
|---|---|---|
| All-cause mortalityDapagliflozinvs Empagliflozin | 0.92 (0.711–1.18) | |
| All-cause mortalityDapagliflozinvs Sotagliflozin | 1.05 (0.68–1.59) | |
| All-cause mortalityEmpagliflozinvs Sotagliflozin | 1.14 (0.74–1.73) | |
| CV deathDapagliflozinvs Empagliflozin | 0.94 (0.71–1.23) | |
| CV deathDapagliflozinvs Sotagliflozin | 0.96 (0.61–1.55) | |
| CV deathEmpagliflozinvs Sotagliflozin | 1.03 (0.64–1.66) | |
| Hospitalization for HFDapagliflozinvs Empagliflozin | 1.13 (0.64–1.97) | |
| Hospitalization for HFDapagliflozinvs Sotagliflozin | 1.56 (0.74–3.15) | |
| Hospitalization for HFEmpagliflozinvs Sotagliflozin | 1.39 (0.68–2.78) | |
| 0.20.5125Odds ratio (log scale) |
All-cause mortality
- No significant difference
CV death
- No significant difference
Hospitalization for HF
- No significant difference
Original publication
Indirect Comparison of SGLT2 Inhibitors in Patients with Established Heart Failure: Evidence Based on Bayesian Methods. ESC Heart Fail. Published 26 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →